XML 79 R42.htm IDEA: XBRL DOCUMENT v3.21.2

Fair value measurements (Tables)

6 Months Ended

12 Months Ended

Jul. 03, 2021

Dec. 31, 2020

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Liabilities Measured At Fair Value on Recurring Basis

The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:

		July 3, 2021												December 31, 2020
		Total				Level 2				Level 3				Total				Level 2				Level 3
Interest rate swap		$	292			$	292			$	—			$	1,602			$	1,602			$	—
Current portion of contingent consideration			13,220				—				13,220				—				—				—
Long-term contingent consideration, less current portion			30,421				—				30,421				—				—				—
Management incentive plan and liability-classified awards			—				—				—				40,303				—				40,303
Equity Participation Right			—				—				—				6,101				—				6,101
Total liabilities		$	43,933			$	292			$	43,641			$	48,006			$	1,602			$	46,404

Schedule of Fair Value Measurement Inputs and Valuation Techniques

After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using the following unobservable Level 3 inputs:

		Valuation Technique		Unobservable inputs		Range
Bioness contingent consideration		Discounted cash flow		Payment discount rate		5.0% - 6.8%
				Payment period		2021 - 2025

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3:

Balance at December 31, 2020		$	40,303
Change in fair value			(25,185	)
Initial estimate (vesting)			829
Payments			(11,281	)
Phantom plan conversion to Class A common stock			(4,666	)
Balance at July 3, 2021		$	—

The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3:

Balance at December 31, 2020		$	6,101
Change in fair value			(2,774	)
Payment			(3,327	)
Balance at July 3, 2021		$	—

Summary of range of key assumptions used within the valuation of the awards

The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3:

Balance at December 31, 2020		$	40,303
Change in fair value			(25,185	)
Initial estimate (vesting)			829
Payments			(11,281	)
Phantom plan conversion to Class A common stock			(4,666	)
Balance at July 3, 2021		$	—

The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3:

Balance at December 31, 2020		$	6,101
Change in fair value			(2,774	)
Payment			(3,327	)
Balance at July 3, 2021		$	—

Bio Ventus LLC [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Liabilities Measured At Fair Value on Recurring Basis

The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs.

		December 31, 2020												December 31, 2019
		Total				Level 2				Level 3				Level 3
Interest rate swap		$	1,602			$	1,602			$	—			$	—
Management incentive plan and liability-classified awards			40,303				—				40,303				40,802
Equity Participation Rights			6,101				—				6,101				5,457
Total liabilities		$	48,006			$	1,602			$	46,404			$	46,259

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3:

Balance at December 31, 2018		$	33,063
Initial estimate (vesting)			5,464
Forfeitures			(1,013	)
Change in fair value			6,290
Payment			(3,002	)
Balance at December 31, 2019			40,802
Initial estimate (vesting)			4,734
Forfeitures			(1,298	)
Change in fair value			6,641
Payment			(10,576	)
Balance at December 31, 2020		$	40,303

The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3:

Balance at December 31, 2018		$	4,892
Change in fair value			565
Balance at December 31, 2019			5,457
Change in fair value			644
Balance at December 31, 2020		$	6,101

Summary of range of key assumptions used within the valuation of the awards

The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3:

Balance at December 31, 2018		$	33,063
Initial estimate (vesting)			5,464
Forfeitures			(1,013	)
Change in fair value			6,290
Payment			(3,002	)
Balance at December 31, 2019			40,802
Initial estimate (vesting)			4,734
Forfeitures			(1,298	)
Change in fair value			6,641
Payment			(10,576	)
Balance at December 31, 2020		$	40,303

The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3:

Balance at December 31, 2018		$	4,892
Change in fair value			565
Balance at December 31, 2019			5,457
Change in fair value			644
Balance at December 31, 2020		$	6,101

Equity Participation Right Unit [Member] | Bio Ventus LLC [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a range of key assumptions used within the valuation of the awards as of December 31, 2020:

Valuation technique		Unobservable inputs		Range		Weighted Average
Option pricing approach		Time to liquidity event		0.4		0.4
		Risk free rate		0.10%		0.10%
		Equality volatility		35.13% - 101.25%		50.0%
		Equity value		$1,065,000 - $1,240,000		$1,145,000
		Lack of marketability discount		7.0%		7.0%

Summary of range of key assumptions used within the valuation of the awards

The following table provides a range of key assumptions used within the valuation of the awards as of December 31, 2020:

Valuation technique		Unobservable inputs		Range		Weighted Average
Option pricing approach		Time to liquidity event		0.4		0.4
		Risk free rate		0.10%		0.10%
		Equality volatility		35.13% - 101.25%		50.0%
		Equity value		$1,065,000 - $1,240,000		$1,145,000
		Lack of marketability discount		7.0%		7.0%

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258

+ Details

Name:	us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=bvs_BioVentusLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: